Phenotype standardization for statin-induced myotoxicity

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 4, 2014, Pages 470-476

  Alfirevic, A ^a   Neely, D ^b   Armitage, J ^c   Chinoy, H ^d   Cooper, R G ^a   Laaksonen, R ^e   Carr, D F ^a   Bloch, K M ^a   Fahy, J ^a   Hanson, A ^a   Yue, Q Y ^f   Wadelius, M ^g   Maitland Van Der Zee, A H ^h   Voora, D ⁱ   Psaty, B M ^j,k   Palmer, C N A ^l   Pirmohamed, M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e Zora Biosciences Oy   (Finland)

^f MEDICAL PRODUCTS AGENCY   (Sweden)

^g UPPSALA UNIVERSITY   (Sweden)

^h UTRECHT UNIVERSITY   (Netherlands)

ⁱ DUKE UNIVERSITY   (United States)

^j UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^k CENTER FOR HEALTH STUDIES   (United States)

^l UNIVERSITY OF DUNDEE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CREATINE KINASE; CYTOCHROME P450 3A4; FIBRIC ACID DERIVATIVE; HMGCR AUTOANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

CLASSIFICATION ALGORITHM; COMORBIDITY; DISEASE CLASSIFICATION; ENZYME INHIBITION; EXERCISE; FATIGUE; HUMAN; INCIDENCE; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE TENDERNESS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOTOXICITY; NECROTIZING AUTOIMMUNE MYOPATHY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; STANDARDIZATION; TIME; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED; CLASSIFICATION; CONSENSUS DEVELOPMENT; MYOSITIS; NOMENCLATURE;

AUTOIMMUNE DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; MYALGIA; MYOSITIS; PHENOTYPE; RHABDOMYOLYSIS; RISK FACTORS; TERMINOLOGY AS TOPIC; TIME FACTORS;

EID: 84920855091     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.121     Document Type: Review

References (70)

1. Law, M. & Rudnicka, A.R. Statin safety: a systematic review. Am. J. Cardiol. 97, 52C-60C (2006).
2. Sathasivam, S. Statin induced myotoxicity. Eur. J. Intern. Med. 23, 317-324 (2012).
3. Stone, N.J. et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013; e-pub ahead of print 12 November 2013.
4. Graham, D.J. et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585-2590 (2004).
5. Staffa, J.A., Chang, J. & Green, L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346, 539-540 (2002).
6. Floyd, J.S., Heckbert, S.R., Weiss, N.S., Carrell, D.S. & Psaty, B.M. Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. JAMA 307, 1580-1582 (2012).
7. Pasternak, R.C., Smith, S.C. Jr, Bairey-Merz, C.N., Grundy, S.M., Cleeman, J.I. & Lenfant, C.; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 106, 1024-1028 (2002).
8. Aithal, G.P. & Daly, A.K. Preempting and preventing drug-induced liver injury. Nat. Genet. 42, 650-651 (2010).
9. Carr, D.F. et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin. Pharmacol. Ther. 94, 695-701 (2013).
10. Chang, C.H., Kusama, M., Ono, S., Sugiyama, Y., Orii, T. & Akazawa, M. Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information. BMJ Open 3, (2013).
11. Pirmohamed, M., Aithal, G.P., Behr, E., Daly, A. & Roden, D. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin. Pharmacol. Ther. 89, 784-785 (2011).
12. Sai, K. et al. Development of a detection algorithm for statin-induced myopathy using electronic medical records. J. Clin. Pharm. Ther. 38, 230-235 (2013).
13. Aithal, G.P. et al. Case definition and phenotype standardization in druginduced liver injury. Clin. Pharmacol. Ther. 89, 806-815 (2011).
14. Behr, E.R. et al. The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. Eur. Heart J. 34, 1958-1963 (2013).
15. Pirmohamed, M. et al. Phenotype standardization for immune-mediated drug-induced skin injury. Clin. Pharmacol. Ther. 89, 896-901 (2011).
16. Agbabiaka, T.B., Savovic, J. & Ernst, E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 31, 21-37 (2008).
17. Cham, S., Evans, M.A., Denenberg, J.O. & Golomb, B.A. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy 30, 541-553 (2010).
18. de Lemos, J.A. et al.; Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292, 1307-1316 (2004).
19. Hansen, K.E., Hildebrand, J.P., Ferguson, E.E. & Stein, J.H. Outcomes in 45 patients with statin-associated myopathy. Arch. Intern. Med. 165, 2671-2676 (2005).
20. Kashani, A. et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114, 2788-2797 (2006).
21. Molokhia, M., McKeigue, P., Curcin, V. & Majeed, A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. PLoS One 3, e2522 (2008).
22. Oshima, Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern. Med. 50, 845-853 (2011).
23. Pfeffer, M.A. et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 105, 2341-2346 (2002).
24. Ridker, P.M. et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
25. Cziraky, M.J. et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J. Clin. Lipidol. 7, 102-108 (2013).
26. Gilad, R. & Lampl, Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin. Neuropharmacol. 22, 295-297 (1999).
27. Meriggioli, M.N., Barboi, A.C., Rowin, J. & Cochran, E.J. HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients. J. Clin. Neuromuscul. Dis. 2, 129-134 (2001).
28. Phillips, P.S. et al.; Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 137, 581-585 (2002).
29. Pierce, L.R., Wysowski, D.K. & Gross, T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264, 71-75 (1990).
30. Hohenegger, M. Drug induced rhabdomyolysis. Curr. Opin. Pharmacol. 12, 335-339 (2012).
31. Elhayany, A., Mishaal, R.A. & Vinker, S. Is there clinical benefit to routine enzyme testing of patients on statins? Expert Opin. Drug Saf. 11, 185-190 (2012).
32. Fung, E.C. & Crook, M.A. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc. Ther. 30, e212-e218 (2012).
33. Lemstra, M., Blackburn, D., Crawley, A. & Fung, R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can. J. Cardiol. 28, 574-580 (2012).
34. Blaier, O., Lishner, M. & Elis, A. Managing statin-induced muscle toxicity in a lipid clinic. J. Clin. Pharm. Ther. 36, 336-341 (2011).
35. Link, E. et al.; SEARCH Collaborative Group. SLCO1B1 variants and statininduced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
36. Wilke, R.A. et al.; Clinical Pharmacogenomics Implementation Consortium (CPIC). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92, 112-117 (2012).
37. Brunham, L.R. et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12, 233-237 (2012).
38. Donnelly, L.A. et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther. 89, 210-216 (2011).
39. Donnelly, L.A. et al. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a metaanalysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenet. Genomics 23, 518-525 (2013).
40. Linde, R., Peng, L., Desai, M. & Feldman, D. The role of vitamin D and SLCO1B1∗5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol. 2, 77-84 (2010).
41. Marciante, K.D. et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics 21, 280-288 (2011).
42. Voora, D. et al. The SLCO1B1∗5 genetic variant is associated with statininduced side effects. J. Am. Coll. Cardiol. 54, 1609-1616 (2009).
43. Newman, C., Tsai, J., Szarek, M., Luo, D. & Gibson, E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am. J. Cardiol. 97, 61-67 (2006).
44. Antons, K.A., Williams, C.D., Baker, S.K. & Phillips, P.S. Clinical perspectives of statin-induced rhabdomyolysis. Am. J. Med. 119, 400-409 (2006).
45. Black, C. & Jick, H. Etiology and frequency of rhabdomyolysis. Pharmacotherapy 22, 1524-1526 (2002).
46. Needham, M., Fabian, V., Knezevic, W., Panegyres, P., Zilko, P. & Mastaglia, F.L. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul. Disord. 17, 194-200 (2007).
47. Mammen, A.L. et al. Autoantibodies against 3-hydroxy-3-methylglutarylcoenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 63, 713-721 (2011).
48. Mammen, A.L. et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res. (Hoboken). 64, 269-272 (2012).
49. Coward, W.R., Marei, A., Yang, A., Vasa-Nicotera, M.M. & Chow, S.C. Statininduced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J. Immunol. 176, 5284-5292 (2006).
50. Bruckert, E., Hayem, G., Dejager, S., Yau, C. & Bégaud, B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc. Drugs Ther. 19, 403-414 (2005).
51. Grable-Esposito, P., Katzberg, H.D., Greenberg, S.A., Srinivasan, J., Katz, J. & Amato, A.A. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41, 185-190 (2010).
52. Jones, P.H. & Davidson, M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95, 120-122 (2005).
53. Backman, J.T., Kyrklund, C., Kivistö, K.T., Wang, J.S. & Neuvonen, P.J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 68, 122-129 (2000).
54. Shitara, Y. & Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112, 71-105 (2006).
55. Kyrklund, C., Backman, J.T., Kivistö, K.T., Neuvonen, M., Laitila, J. & Neuvonen, P.J. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69, 340-345 (2001).
56. Kyrklund, C., Backman, J.T., Neuvonen, M. & Neuvonen, P.J. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 73, 538-544 (2003).
57. Schneck, D.W. et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75, 455-463 (2004).
58. Ozdemir, O., Boran, M., Gökçe, V., Uzun, Y., Koçak, B. & Korkmaz, S. A case with severe rhabdomyolysis and renal failure associated with cerivastatingemfibrozil combination therapy-a case report. Angiology 51, 695-697 (2000).
59. Ray, G.M. Antiretroviral and statin drug-drug interactions. Cardiol. Rev. 17, 44-47 (2009).
60. Sorokin, A.V., Duncan, B., Panetta, R. & Thompson, P.D. Rhabdomyolysis associated with pomegranate juice consumption. Am. J. Cardiol. 98, 705-706 (2006).
61. Zhou, S., Chan, E., Li, X. & Huang, M. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther. Clin. Risk Manag. 1, 3-13 (2005).
62. Zhou, S. et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44, 279-304 (2005).
63. Mazokopakis, E.E. Unusual causes of rhabdomyolysis. Intern. Med. J. 38, 364-367 (2008).
64. Dirks, A.J. & Jones, K.M. Statin-induced apoptosis and skeletal myopathy. Am. J. Physiol. Cell Physiol. 291, C1208-C1212 (2006).
65. Sinzinger, H. & O'Grady, J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br. J. Clin. Pharmacol. 57, 525-528 (2004).
66. O'Meara, H. et al. Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink. Br. J. Clin. Pharmacol. 77, 831-838 (2014).
67. Bays, H. Statin safety: an overview and assessment of the data-2005. Am. J. Cardiol. 97, 6C-26C (2006).
68. Moghadasian, M.H., Mancini, G.B. & Frohlich, J.J. Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. Expert Opin. Pharmacother. 1, 683-695 (2000).
69. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
70. Mohassel, P. & Mammen, A.L. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 48, 477-483 (2013).